Probiotics for Gout / Hyperuricemia: A Randomized, Intervention, Parallel Controlled, Multicenter Clinical Trial
Sponsored by The Affiliated Hospital of Inner Mongolia Medical University
About this trial
Last updated 2 years ago
Study ID
Status
Type
Phase
Placebo
Accepting
Not accepting
Trial Timing
Ended a year ago
What is this trial about?
What are the participation requirements?
Inclusion Criteria
Subjects are eligible for inclusion in this study only if they meet all of the following criteria 1. 18-70 years old, gender unlimited ; 2. Previous history of gout ; 3. According to the criteria of gout classification and diagnosis of EULAR / ACR in 2015; 4. fasting serum uric acid ≥ 480 μ mol / L (8mg / dl)
Exclusion Criteria
If the subjects meet any of the following criteria, they will not be selected : 1. Gout in the past two weeks ; 2. Secondary hyperuricemia ; 3. Patients with abnormal liver and kidney function (ALT, AST are 1.5 times higher than the normal value, Cr is 1.5 times higher than the upper limit of the normal value; 4. WBC < 4.0 × 109 / L, PLT < 100 × 109 / L, HGB < 90g / L, or other hematological diseases ; 5. bad blood pressure control (BP>160mmHg/100 mmHg) 6. Type I diabetes or poorly controlled type II diabetes: fasting blood glucose ≥ 8.5mmol/l ; 7. Patients with active peptic ulcer ; 8. Patients with gastrointestinal cancer ; 9. Patients with previous intestinal diseases such as lactose intolerance, irritable bowel syndrome, inflammatory bowel disease and habitual diarrhea ; 10. Use of drugs that affect the metabolism or excretion of uric acid and cannot / cannot be stopped, including azathioprine, 6-mercaptopterin, thiazide diuretics, aspirin (more than 325mg / day) or other salicylates ; 11. Those who need continuous prednisone treatment ; 12. Those who need antibiotic treatment for infectious diseases ; 13. Those with body mass index (BMI) greater than 30 ; 14. people with alcoholism ; 15. People with a history of allergy to Lactobacillus and its products or with high sensitive constitution ; 16. Researchers who have received other drugs within 3 months before screening ; 17. The people who are researchers thinks it is not suitable to participate in the study.